^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Small Intestinal Carcinoma

    7d
    New Technique of Pancreaticojejunostomy During Whipple Operation (clinicaltrials.gov)
    P=N/A, N=48, Completed, Theodor Bilharz Research Institute | Phase classification: P4 --> P=N/A
    Phase classification
    11d
    Interlesional Genomic Heterogeneity in Small Bowel Adenocarcinoma: Evidence from Matched Primary and Peritoneal Metastatic Lesions. (PubMed, Clin Res Hepatol Gastroenterol)
    In contrast, one of the two cases with metachronous peritoneal metastases developed an additional KRAS mutation compared to the paired primary, shifted from moderately to poorly differentiated morphology, and exhibited mismatch-repair deficiency by immunohistochemistry, while remaining microsatellite stable by NGS. These findings suggest interlesional molecular heterogeneity in SBA and emphasize the need for re-biopsies in precision oncology for metachronous metastases.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation
    11d
    Clinico-pathological diagnostic and prognostic biomarkers for duodenal adenocarcinoma from a UK retrospective Cohort study. (PubMed, Hum Pathol)
    Our work presents the largest UK cohort of DA with long-term follow-up making it an excellent resource for future biomarker studies. Validation studies in prospective clinical studies are required for clinical application.
    Retrospective data • Journal
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • KRT20 (Keratin 20) • BECN1 (Beclin 1)
    13d
    Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays (clinicaltrials.gov)
    P=N/A, N=420, Recruiting, Alliance for Clinical Trials in Oncology | Not yet recruiting --> Recruiting
    Enrollment open
    |
    5-fluorouracil • oxaliplatin • leucovorin calcium
    13d
    A retrospective analysis of taxane-based chemotherapy in small bowel adenocarcinoma. (PubMed, Oncologist)
    Taxane-based therapy demonstrated activity in metastatic SBA, with 24% response and 3.1-month mTTP. TP53 mutation may be a negative predictive marker for taxane efficacy. These findings support prospective investigation in metastatic SBA.
    Retrospective data • Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • SMAD4 (SMAD family member 4)
    |
    TP53 mutation • KRAS mutation
    18d
    Gastric-Type Adenomas of the Nonampullary Duodenum: Reappraisal of Clinicopathological and Molecular Features and a Proposal for Novel Classification. (PubMed, Am J Surg Pathol)
    These findings suggest that nonampullary duodenal neoplasms of gastric phenotype can be reclassified as "gastric-type adenomas" based on excellent prognosis and common genetic alterations, albeit a wide spectrum of morphology and gastric phenotypic expression. MDM2 amplification may contribute to histologic progression.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • MDM2 (E3 ubiquitin protein ligase) • GNAS (GNAS Complex Locus)
    |
    KRAS mutation
    19d
    CRN00808-11: Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome (clinicaltrials.gov)
    P2, N=36, Completed, Crinetics Pharmaceuticals Inc. | Active, not recruiting --> Completed
    Trial completion
    |
    Palsonify (paltusotine)
    22d
    iCARE4Lynch: Small Bowel Capsule Endoscopy in Lynch Syndrome (clinicaltrials.gov)
    P=N/A, N=400, Recruiting, Assistance Publique - Hôpitaux de Paris
    New trial
    |
    MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • EPCAM (Epithelial cell adhesion molecule)
    22d
    JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation (clinicaltrials.gov)
    P1/2, N=48, Active, not recruiting, Allist Pharmaceuticals, Inc. | Trial completion date: Jan 2026 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Apr 2025
    Trial completion date • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Erbitux (cetuximab) • Airuikai (glecirasib)
    22d
    Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation Therapy (clinicaltrials.gov)
    P1, N=19, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Mar 2027
    Trial completion date
    |
    CD4 (CD4 Molecule)
    |
    ropidoxuridine (IPdR)
    22d
    Diffuse large B-cell lymphoma as a rare cause of small bowel obstruction: case report and literature review. (PubMed, Int J Surg Case Rep)
    The postoperative course was uneventful and the patient remained disease-free at 8-month follow-up after completing R-CHOP chemotherapy...Although rare, DLBCL should be considered as a differential diagnosis in unexplained SBO. Early recognition and a multidisciplinary management strategy improve prognosis.
    Journal
    |
    CD20 (Membrane Spanning 4-Domains A1) • BCL6 (B-cell CLL/lymphoma 6) • MME (Membrane Metalloendopeptidase)
    |
    CD20 positive
    |
    Rituxan (rituximab)
    27d
    Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas (clinicaltrials.gov)
    P1/2, N=55, Completed, University of Chicago | Active, not recruiting --> Completed
    Trial completion
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • BCL6 (B-cell CLL/lymphoma 6) • IRF4 (Interferon regulatory factor 4) • MME (Membrane Metalloendopeptidase)
    |
    Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • prednisone • melphalan